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Irsogladine is a commonly used anti-gastric ulcer agent in Japan, and recent in vivo studies have 
shown it to have anti-angiogenic properties. The exact role of irsogladine as an inhibitor of 
angiogenesis remains uncertain. In this study, we show that irsogladine inhibited breast cancer 
regrowth and pulmonary metastasis but had no anti-angiogenic function against HUVEC cells. 
Irsogladine failed to inhibit proliferation, tubular formation, and the uPA/MMP-1 mRNA 
expression of HUVEC cells. We also examined the effect of irsogladine in an orthotopic 
transplant model of human breast cancer metastasis in athymic mice. Human MDA-MB-435 
cells were injected into the mammary fat pads. After nine weeks, the tumors were resected 
under general anesthesia. Irsogladine or vehicle was given p.o. daily thereafter. Daily 
administration of irsogladine at 120 mg/kg/day over a five-week period had no effect on the 
body weight of the mice. Tumor regrowth, average volume of pulmonary metastases, and the 
number of metastases were inhibited by 40, 48 and 64%, respectively. These results suggest 
that irsogladine may be useful in the breast cancer adjuvant setting. 
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New blood vessel formation (angiogenesis) is mandatory for growth of breast cancer, and the 
development within tumor tissues has been implicated in invasion and metastasis in breast 
cancer, melanoma, prostatic cancer, and other cancers [1, 2]. An effective vessel-targeting 
therapy should be useful for many types of cancer because delivering the drug to the vessels 
should be much easier than getting it into all the cells of a solid tumor. Several anti-angiogenic 
agents are currently undergoing clinical trials [3, 4]. These include interferons [5], tetracycline 
[6], tamoxifen [7] and thalidomide [8]. 
 Irsogladine has been clinically used as an anti-gastric ulcer agent in Japan, where it acts 
to strengthen intercellular gap junctions [9]. Irsogladine has been found to inhibit the induction 
of tissue-type plasminogen activator (tPA) synthesis in endothelial cells and angiogenesis in 
both in vitro and in vivo models [10]. Recently, irsogladine has also been shown to have 
anti-tumor activity in murine xenograft models of epidermoid cancer and glioma [11]. To date 
no work has been performed evaluating irsogladine in breast cancer. In the present study, we 
investigated the effect of irsogladine in a human breast cancer-athymic nude mouse system 
[12], specifically looking at local-regional tumor regrowth and the formation of pulmonary  





Materials and methods 
 
Cell culture and drugs 
 
Human MDA-MB-435 breast cancer cells (a gift from Dr. Janet Price, The University of Texas 
M. D. Anderson Cancer Center, Houston) were cultured in minimum essential medium (Life 
Technologies [GIBCO BRL], Gaithersburg, MD) supplemented with multi-vitamins, sodium 
pyrophosphate (100 mM), penicillin (105 U/100 ml), streptomycin (10 µg/100 ml) and fetal calf 
serum (5%) (supplements from Sigma Chemical Co., St. Louis, MO) in a 5% CO2-air 
atmosphere at 37°C. The HUVEC umbilical vein cell kit and recombinant human vascular 
endothelial cell growth factor (VEGF) were obtained from Clonetics (San Diego, CA) and 
Genentech Inc. (South San Francisco), respectively. Irsogladine and VEGF were freshly 
prepared for each experiment. 
 
Cell proliferation assay 
 
Cell proliferation was determined using the CellTilter Aqueous nonradioactive cell 
proliferation assay (Promega Corp., Madison, WI). Cultured cells (5 x 103 cells/well) were 
plated with various doses of irsogladine into 96-well tissue culture plates (Costar, Cambridge, 
MA). After 48 h, 20 µl/well of combined tetrazolium/phenazine methosulfate solution was 
added. After 60 min at 37°C in a 5% CO2-air atmosphere, an absorbance reading at 450 nm was 
measured using Elx 800 (Bio-Tek Instruments, Inc., Winooski, VT). The results are reported as 
a percentage of untreated control cells. Each group has eight wells. 
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Tubular formation assay 
 
HUVEC cells (4 x 104 cells/well) were seeded on gels of growth factor reduced Matrigel matrix 
(Becton Dickinson, Bedford, MA) with or without VEGF (10 ng/ml) and/or irsogladine (100 
µM) into 24-well tissue culture plates (Costar). After 24 h, microscopic pictures of each well 
were taken and the total length of tubular formation per field was measured using a road map 
pen (American Map, Maspeth, NY). Eight random fields were measured and the total length per 
field was calculated. 
 
Northern blot analysis 
 
HUVEC cells were incubated with or without VEGF (10 ng/ml) and/or irsogladine (100 µM) 
for 24 h. Total RNA was extracted and subjected to northern blotting as described previously 
[13, 14]. Briefly, the RNA was fractionated on 1% agarose gel containing 2.2 M formaldehyde, 
and transferred to an Optitran membrane (Schleicher and Schuell, Inc., Keene, NH). The 
membranes were baked in a vacuum oven at 80°C, prehybridized, hybridized, washed, and 
exposed to an X-ray film with an intensifying screen at -80°C. The probes specific for human 
urokinase-type plasminogen activator (uPA), matrix metalloproteinase-1 (MMP-1) and ß-actin 
were an 1.5-kb Pst I-Pst I fragment of pEMBL8, a 2.0-kb EcoRI-Pst I fragment of pSP64 and an 
1.4-kb EcoRI-EcoRI fragment of pBluescript SK-, respectively. All plasmids were obtained 
from the American Type Culture Collection, Rockville, MD. After exposure to X-ray film and 
development, expression was measured densitometrically using Adobe Photoshop 4.0 (Adobe 
System Inc., Seattle, WA). Relative levels of specific uPA and MMP-1 mRNA were compared 
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after normalization by dividing each expression densitometrically by that of ß-actin on the 
same filter. 
 
Human breast cancer xenograft-nude mouse model 
 
The nude mouse xenograft model was performed as described previously by Sledge et al. [12]. 
Briefly, female BALB/c nude mice (Harlan Sprague Dawley, Indianapolis, IN), six to eight 
weeks old, were used. MDA-MB-435 cells (5 x 105 cells/mouse) were injected into the 
mammary fat pads of 40 nude mice. After nine weeks, the tumors were resected under general 
anesthesia. Irsogladine, suspended in 0.5% sodium carboxymethylcellulose (vehicle), was 
given p.o. daily thereafter. The control mice were given only vehicle. The administrations were 
continued through week 14. The lungs were removed and fixed in Bouin's solution. 
Macroscopically visualized tumors were enumerated and measured. Tumor volume was 
calculated as (length) x (width)2 /2. Animal experiments were performed according to NIH 




Statistical analysis was performed using Statview (version 4.02; Abacus Concepts, Berkeley, 




Irsogladine has been shown to specifically inhibit proliferation of vascular endothelial cells 
[11]. We examined the effect of irsogladine on the proliferation of HUVEC and 
MDA-MB-435. Irsogladine at 100 µM inhibited the proliferation of HUVEC and 
MDA-MB-435 by 15% but had no effect at one and 10 µM (data not shown). There was no 
difference between the two cell lines. As shown in Figure 1, VEGF induced tubular formation 
by HUVEC cells, but irsogladine did not block the stimulatory effect of VEGF. Although 
irsogladine has been found to inhibit the induction of tPA mRNA in epidermal growth factor 
(EGF) treated endothelial cells [10], irsogladine has no effect on the uPA/ MMP-1 cascade in 
HUVEC cells incubated without growth factors for 24 h in a serum free medium (Table 1). 
 We have previously used an athymic mouse model of human breast cancer to evaluate 
the effect of anti-angiogenic agents on tumor regrowth and metastasis [12]. Eight of 40 primary 
tumor-bearing mice died during tumor resection and 34 survival mice were used for the 
following study. Daily administration of irsogladine at 120 mg/kg/day over a 5-week period did 
not affect the body weight of the mice, though one of 18 control mice died before the study was 
completed. Primary tumor regrowth occurred in 14 of 16 irsogladine-treated mice and all of 
vehicle-treated controls. As shown in Table 2, orally delivered irsogladine inhibited tumor 
regrowth by 40% of control. 
 As shown in Table 2, daily treatment with irsogladine at 120 mg/kg/day decreased the 
incidence, the volume, and the number of pulmonary metastases. Only one of 17 control mice 
failed to develop pulmonary metastases, compared with five of 16 irsogladine-treated mice. 






In our laboratory, we have used a human breast cancer-athymic nude mouse model system to 
evaluate the effect of adjuvant anti-angiogenic therapy after primary tumor resection [12]. In 
this system, tumor regrowth and spontaneous pulmonary metastasis were inhibited by 
irsogladine orally administered after primary tumor resection. 
 Irsogladine, which has been clinically used as an anti-gastric ulcer agent in Japan, has 
been reported to have efficacy in metastatic [15] and inoperable gastric cancer [16] when 
combined with UFT (a mixture of tegafur and uracil in a molar ratio of 1:4). Experimentally, 
irsogladine has been shown to inhibit angiogenesis [10, 11] and carcinogenesis [17, 18]. 
 Irsogladine, a potent inhibitor of angiogenesis, has been found to inhibit the induction 
of tPA mRNA in EGF-treated endothelial cells [10]. In human breast cancer, uPA rather than 
tPA has been shown to play a more important role both in tumor-related angiogenesis and as a 
prognostic agent [19], and MMPs have been shown to be involved in endothelial cells during 
the angiogenic process [20, 21]. We examined the hypothesis that irsogladine might affect the 
uPA/MMP cascade in vascular endothelial cells. Irsogladine failed to inhibit proliferation, 
tubular formation, and the uPA/MMP-1 mRNA expression of human vascular endothelial cells. 
These results suggest that HUVEC cells might be not responsive to irsogladine. 
 Sato et al. [10] have suggested that an anti-angiogenic effect of irsogladine may be 
general and not restricted to the effect of EGF. The reason was that the angiogenic potential of 
human omental microvascular endothelial cells, which had not produced EGF [22], was not 
related to EGF. Ren et al. [23] have suggested that the mechanism may be independent of 
plasminogen activation in vivo because the agent inhibited bFGF-induced angiogenesis in 
tPA-knockout and uPA-knockout mice. In addition, irsogladine has been reported to upregulate 
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intercellular communication via gap junctions between cultured rabbit gastric endothelial cells 
[9], and the junctional communication has been reported to be induced in migrating vascular 
endothelial cells [24]. Irsogladine upregulated expressions of connexin26 and 32, gap junction 
proteins, in the rat liver [25]. These findings suggest that the modulation of gap junctional 
intercellular communication by irsogladine might correlate to its anti-angiogenic effect, but the 
exact role of irsogladine as an inhibitor of angiogenesis remains uncertain. 
 Irsogladine modestly inhibited not only tumor regrowth of MDA-MB-435 mammary fat 
pad tumors but pulmonary metastases and might be a unique and useful drug in treatment of 
breast cancer adjunctive to surgery. Further study is required to clarify the mechanism by which 




We thank Dr. Harikrishana Nakshatri for his advice and fruitful discussion and Joanne Dunn, 
MS and Sean Sissons, MS for their technical assistance. This work was supported by the 





1. Weidner N, Semple JP, Welch WR, Folkman J: Tumor angiogenesis and metastasis 
correlation in invasive breast carcinoma. N Engl J Med 324: 1-8, 1991 
 
2. Fidler LJ, Ellis LM: The implications of angiogenesis for the biology and therapy of cancer 
metastasis. Cell 79: 85-88, 1994 
 
3.  Barinaga M: Designing therapies that target tumor blood vessels. Science 275: 482-484, 
1997. 
 
4.  Twardowski P, Gradishar WJ: Clinical trial of antiangiogenic agents. Curr Opin Oncol 9: 
584-589, 1997 
 
5.  Tsuruoka N, Sugiyama M, Tawaragi Y, Tsujimoto M, Nishihara T, Goto T, Sato N: 
Inhibition of in vitro angiogenesis by lymphotaxin and interferon-gamma. Biochem 
Biophys Res Commun 155: 429-435, 1988 
 
6.  Tamargo RJ, Bok RA, Brem H: Angiogenesis inhibition by minocycline. Cancer Res 51: 
672-675, 1991 
 




8.  D'Amato RJ, Loughnan MS, Flynn E, Folkman J: Thalidomide is an inhibitor of 
angiogenesis. Proc Natl Acad Sci USA 91: 4082-4085, 1994 
 
9.  Ueda F, Kyoi T, Mimura K, Kimura K, Yamamoto M: Intercellular communication in 
cultured rabbit gastric epithelial cells. Jpn J Pharmacol 57: 321-328, 1991 
 
10.  Sato Y, Morimoto A, Kiue A, Okamura K, Hamanaka R, Kohno K, Kuwano M, Sakata, T: 
Irsogladine is a potent inhibitor of angiogenesis. FEBS Lett 322: 155-158, 1993 
 
11.  Ono M, Kawahara N, Goto D, Wakabayashi Y, Ushiro S, Yoshida S, Izumi H, Kuwano M, 
Sato Y: Inhibition of tumor growth and neovascularization by an anti-gastric ulcer agent, 
irsogladine. Cancer Res 56: 1512-1516, 1996 
 
11.  Sledge GW Jr., Qulali M, Goulet R, Bone EA, Fife R: Effect of matrix metalloproteinase 
inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice. J Natl 
Cancer Inst  87: 1546-1550, 1995 
 
13.  Nozaki S, Sledge GW Jr, Nakshatri H: Cancer cell-derived interleukin 1alpha contributes 
to autocrine and paracrine induction of pro-metastatic genes in breast cancer. Biochem 
Biophys Res Commun 275: 60-62, 2000 
 
14.  Patel NM, Nozaki S, Shortle NH, Bhat-Nakshatri P, Newton TR, Rice S, Gelfanov V, 
Boswell SH, Goulet RJ Jr, Sledge GW Jr, Nakshatri H: Paclitaxel sensitivity of breast 
 12
cancer cells with constitutively active NF-kappaB is enhanced by IkappaBalpha 
super-repressor and parthenolide. Oncogene 19: 4159-4169, 2000 
 
15.  Hosokawa T, Otani Y, Ogawa K, Kajiwara T: Complete disappearance of metastatic 
abdominal tumors from gastric cancer after treatment with irsogladine maleate. J Cancer 
Res Clin Oncol 118: 565-566, 1992 
 
16.  Hosokawa T, Ogawa K, Otani Y, Kajiwara T: Two cases of gastric cancer remarkably 
reduced with a combined dosage of irsogladine maleate preparation and UFT. Oncol Rep 
1: 93-95, 1994 
 
17.  Sugie S, Okamoto K, Ueda F, Watanabe T, Tanaka T, Mori H: Suppressive effect of 
irsogladine maleate on diethylnitrosamine-initiated and phenobarbital-prompted 
hepatocarcinogenesis in male F344 rats. Jpn J Cancer Res 89: 371-376, 1998 
 
18.  Hirose Y, Tanaka T, Makita H, Yang M, Satoh K, Hara A, Maeda M, Toriyama HB, Mori 
H, Tsuda H: Suppressing effects of 6-(2,5-dichlorophenyl)-2,4-diamino-1,3,5-triazine and 
related synthetic compounds on azoxymethane-induced aberrant crypt foci in rat colon. 
Jpn J Cancer Res 87: 549-554, 1996 
 
19.  Janicke F, Schmitt M and Graeff H: Clinical relevance of the urokinase-type and 
tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin 




20.  Hanemaaijer R, Koolwijk P, le Clercq L, de Vree WJ, van Hinsbergh VW: Regulation of 
matrix metalloproteinase expression in human vein and microvascular endothelial cells. 
Effects of tumour necrosis factor alpha, interleukin 1 and phorbol ester. Biochem J 296: 
803-809, 1993 
 
21.  Fisher C: Gilbertson-Beadling S, Powers EA, Petzold G, Poorman R, Mitchell MA: 
Interstitial collagenase is required for angiogenesis in vitro. Dev Biol 162: 499-510, 1994 
 
22.  Okamura K, Sato Y, Matsuda T, Hamanaka R, Ono M, Kohno K, Kuwano M: Endogenous 
basic fibroblast growth factor-dependent induction of collagenase and interleukin-6 in 
tumor necrosis factor-treated human microvascular endothelial cells. J Biol Chem 266: 
19162-19165, 1991 
 
23.  Ren CJ, Ueda F, Roses DF, Harris MN, Mignatti P, Rifkin DB, Shapiro RL: Irsogladine 
maleate inhibits angiogenesis in wild-type and plasminogen activator-deficient mice. J 
Surg Res 77: 126-131, 1998 
 
24.  Pepper MS, Spray DC, Chanson M, Montesano R, Orci L, Meda P: Junctional 
communication is induced in migrating capillary endothelial cells. J Cell Biol 109: 
3027-3038, 1989 
 
Table 1. Level of uPA and MMP-1 mRNA in HUVEC cells 
 
 Control Irsogladine VEGF VEGF + Irsogladine 
uPA/ß-actina 0.51 0.57 0.52 0.63 
MMP-1/ß-actina 1.36 1.24 0.99 0.97 
aRelative levels of specific uPA and MMP-1 mRNA were compared after normalization by dividing each expression densitometrically 




Table 2. Effect of irsogladine on human breast cancer xenograft-nude mouse model 
 
 Control (n = 17) Irsogladine (n = 16) IRa (%) p valueb
Primary tumor regrowth 17/17 (100%) 14/16 (88%) - .23 
Volume of regrowth tumor (mm3)     7389 ± 1346 c 4466 ± 832 39.6 .08 
Without pulmonary metastases 1/17 (5.9%) 5/16 (31%) - .04 
Number of metastases 13.3 ± 5.2   4.8 ± 1.3 63.9 .14 
Volume of metastases (mm3)    37.8 ± 11.4 19.5 ± 5.9 48.4 .17 
aIR (inhibition ratio) = {1-(irsogladine treated group/control group)} x 100 
bby Fisher’s exact probability or Student’s t test 




Figure 1. Effect of irsogladine on tubular formation by VEGF-treated HUVEC cells. HUVEC 
cells were seeded on gels of growth factor reduced Matrigel matrix with or without VEGF (10 
ng/ml) and/or irsogladine (100 µM) into 24-well tissue culture plates. After 24 h, microscopic 
pictures of each well were taken and the total length of tubular formation per field was 
measured. Eight random fields were measured and the total length per field was calculate. Total 
length is represented as mean length ± SE. 
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